The earnings call revealed challenges with declining sales and profitability due to market constraints, particularly in the instrument sales segment. However, strategic adjustments like the divestment of non-core assets and focus on cash flow improvements demonstrate proactive measures to stabilize and grow the business. The long-term strategy remains promising with growth in lab automation.
Company Guidance
During BICO's Q3 2024 earnings call, CEO Maria Forss and CFO Jacob Thordenberg provided detailed guidance on the company's performance and strategic direction. The company reported sales of SEK 496 million, reflecting a negative organic growth of 13% due to a soft market in the Academia and Diagnostics segments. Despite the sales decline, BICO maintained profitability across all business areas, achieving an adjusted EBITDA margin of 8% with an EBITDA of SEK 40 million and operating cash flow of SEK 45 million. The strategic priorities were highlighted, including a focus on commercial excellence and operational improvements. BICO's new business area structure, comprising Lab Automation, Life Science Solutions, and Bioprinting, was emphasized, with Lab Automation showing a year-to-date organic growth of 26%, despite fluctuations in quarterly revenues. The call also covered the divestment of Nanoscribe and the repurchase of convertible bonds, aiming to optimize capital structure and reduce long-term debt. Additionally, a 20% workforce reduction in CELLINK was announced, expected to save SEK 40 million annually, aligning with BICO's sharpened commercial agenda and strategic focus on profitability and market positioning.
Strong Year-To-Date Organic Growth in Lab Automation
Despite a soft Q3, the Lab Automation business area achieved a year-to-date organic growth of 26%, indicating strong demand for integrated lab automation solutions.
Successful Divestment of Nanoscribe
BICO announced the divestment of Nanoscribe, generating a capital gain of approximately 10% above book value, aligning with the updated strategy to focus on core business areas.
Improvement in Cash Flow
Operating cash flow for Q3 2024 amounted to SEK 45 million, with a positive effect from changes in working capital.
---
BICO Group AB Class B (CLLKF) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLLKF Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 26, 2024
$3.36
$2.76
-17.86%
Aug 20, 2024
$4.20
$4.05
-3.57%
May 07, 2024
$4.18
$3.64
-12.92%
Feb 20, 2024
$4.53
$4.21
-7.06%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BICO Group AB Class B (CLLKF) report earnings?
BICO Group AB Class B (CLLKF) is schdueled to report earning on Feb 19, 2025, Before Open Not Confirmed.
What is BICO Group AB Class B (CLLKF) earnings time?
BICO Group AB Class B (CLLKF) earnings time is at Feb 19, 2025, Before Open Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.